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Symptoms of Multiple Sclerosis (MS) are related to a progressive and strong impact
on patient’s quality of life (QoL). PRIMUS questionnaire is a MS-specific-instrument
to assess QoL. OBJECTIVES: To assess QoL in MS patients using the PRIMUS ques-
tionnaire and the relationships between QoL, disease duration and EDSS disability.
MATERIAL AND METHODS: Non-interventional, cross-sectional and multicenter
study. A total of 261 patients, 17 years with relapsing-remitting or secondary-
progressive MS (RRMS/SPMS), treated with interferon beta-1b (6 months). PRIMUS
questionnaire has three subscales: symptoms, activity limitations and QoL. For the
present study, self-assessed changes were evaluated for QoL (0-22 score) and ac-
tivity limitation (0-38 score) subscales. The higher scores the better QoL and the
greater activity limitation. Correlations between PRIMUS-QoL and EUROQoL-5D,
and with visual analog scale (VAS) were evaluated using Spearman-coefficient (S).
RESULTS: Mean (SD) age was 41.7(10.3) years (61.3% women), 83.9% were RRMS
diagnosed. Mean time since diagnosis was 7.65.8 years, higher in SPMS (6.9 5.2
vs. 11.27.4, p0.0001). Mean EDSS disability was 2.61.75 (5.11.3 SPMS vs.
2.11.4 RRMS, p0.0001). PRIMUS-QoL was better in RRMS patients: 18.36.8 vs.
9.97.1 (p0.0001), getting worse as time from diagnosis increased (p0.01) and
with patient’s disability (18.86.6 in early stages [EDSS3.5] and 8.46.3 in ad-
vanced ones [EDSS5], p0.0001). PRIMUS-activity showed a relationship between
loss of activity with disease duration (p0.0001) and patient’s disability (p0.0001).
PRIMUS-QoL showed a strong negative correlation (S-0.7869) with EUROQoL-5D
(as higher EUROQoL scores indicate worse QoL) and positive correlation with the-
VAS (S 0.7272). PRIMUS-activity showed a very strong correlation (S0.8179) with
EUROQoL-5D as well as a strong negative correlation (S-0.7571) with the VAS.
CONCLUSIONS: The QoL of MS patients changes according to the disease types and
disability levels, and it progressively worsens with disease duration. PRIMUS ques-
tionnaire has demonstrated to be a good tool for assessing QoL and activity in MS
patients.
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OBJECTIVES:The PDQ-Carer is a 29 item measure of health related quality of life for
use with carers of people with Parkinson’s disease. The original development of the
instrument identified four sub domains measured by the instrument. This study
examined the possibility that the four domains could reasonably be summed to
also provide a single summary index score.METHODS: The PDQ-Carer was admin-
istered in a postal survey of patients and carers registered with local branches of
the Parkinson’s Disease Society of Great Britain. Data from the four dimensions of
the PDQ-Carer was subjected to higher order factor analyses. This produced a
single factor suggesting that a single index can be calculated from the measure.
Content validity of the measure was assessed by correlating results with the ‘Gen-
eral Health Perceptions’ scale of the SF-36, a generic measure of health status.
RESULTS: A total of 236 carer questionnaires were returned, a response rate of
60.9%. The mean age of the sample was 68.2 years (SD 9.49; range 25-89 years);
63.5% females, 21.3% males. Higher order principle components factor analysis
produced one factor, accounting for 85.5% of the variance. Consequently it was
decided that the scores of the four domains could be summed to produce a single
index figure. The psychometric properties of this index were explored using reli-
ability tests and tests of construct validity. The newly derived single index was
found to be both internally reliable (alpha0.94) and supported by construct valid-
ity (correlation with GHP0.50, p0.001).CONCLUSIONS:The analysis undertaken
here indicates that data from the PDQ-Carer can be presented in summary form.
The index will provide an overall indication of the impact of caring. Furthermore,
the single index reduces the number of statistical comparisons, and hence the role
of chance, when exploring data from the PDQ-Carer.
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OBJECTIVES: To report the impact of BG-12 (dimethyl fumarate) on patient health-
related quality of life (HRQoL) in CONFIRM, a 2-year, placebo-controlled study of
efficacy and safety of BG-12 in patients with relapsing–remitting multiple sclerosis
(RRMS). METHODS: Patients aged 18–55 years with RRMS (McDonald criteria 2005)
and Expanded Disability Status Scale score 0–5.0 were randomized 1:1:1:1 to oral
BG-12 240 mg twice (BID) or three times daily (TID), placebo, or subcutaneous glati-
ramer acetate (GA) 20 mg/day (reference comparator arm). A Short Form (SF)-36
questionnaire was administered to assess health status and HRQoL on 8 multi-item
100-point scales at baseline, 24 weeks, 1 year and 2 years. These scores were used
to calculate Physical Component Summary (PCS) and Mental Component Sum-
mary (MCS) scores. In addition, patients’ global impression of well-being was as-
sessed at baseline and every 3 months using a 100-point visual analogue scale
(VAS). Higher scores indicated better HRQoL. RESULTS: The intent-to-treat popu-
lation comprised 1,417 patients. Mean PCS scores increased from baseline to 2
years with BG-12 BID (0.49) and TID (0.33) versus a decrease with placebo
(0.71), indicating significantly improved (BID)/a trend toward better (TID) physical
health and well-being relative to placebo (p0.0217 and p0.0519, respectively).
With GA, mean PCS score increased by 0.42 at 2 years (p0.0259 versus placebo).
SF-36 MCS scores showed similar trends but results were not statistically signifi-
cant. Mean changes from baseline to 2 years in VAS scores were 0.3, 0.3 and 2.1
with BG-12 BID, TID and GA, respectively, versus 3.9 with placebo (p0.0003,
p0.0025 and p0.0001, respectively), indicating a significantly improved sense of
well-being with active treatment. CONCLUSIONS: Together with the significant
improvement in clinical and neuroradiological measures, benefits on patient-re-
ported HRQoL further support the potential for BG-12 to become a valuable oral
treatment option for patients with relapsing MS.
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OBJECTIVES:Huntington’s disease (HD) is a neurodegenerative disease that causes
movement disorders, and cognitive and psychological deterioration; leading to
considerable burden for patients and their families. The paucity of research into
the impact of HD on the quality of life (QoL) of family carers led Aubeeluck and
Buchanan to develop and validate a disease-specific QoL measure to evaluate care-
givers’ QoL, and assess the efficacy of therapeutic interventions. This current study
aimed to validate a shortened version of the HD QoL Battery for Carers (HDQoL-C)
in France and Italy. METHODS: The shortened version of the HDQoL-C comprised
two components: the satisfaction with life component (3 items) and the feelings
about living with HD(17 items). It was translated forwards and backwards by native
speakers. 301 family carers completed the questionnaire. While face validity was
studied through item completion, internal validity was evaluated using factorial
structure and internal consistency. Differential item functioning (DIF) analyses
were also performed to test whether all items behaved in the same manner among
the country subgroups. External validation was tested using known-group compar-
ison analyses between three severity subgroups, according to dependence, global
clinical severity and motor severity. RESULTS: The translated short version
showed satisfactory face validity with few missing data (up to 6%) and a good
reliability despite the item reduction (Cronbach’s alpha coefficients of around 0.8
for both components). The factor analysis was comparable to the original version,
with the variable distribution according to the two factors being the same. No
significant DIF between France and Italy was detected. Carers who cared for pa-
tients with less clinically severe symptoms of HD reported significantly better QoL
than carers of patients with more clinically severe symptoms. CONCLUSIONS:
These findings indicate that the HDQoL-C is multi-lingual, multi-cultural and eas-
ily applicable in other languages.
PND60
NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN IS UNDERDIAGNOSED IN GP
PRACTICES ALTHOUGH IT HAS HIGH IMPACT ON PATIENTS’ HEALTH RELATED
QUALITY OF LIFE
Brodszky V1, Komoly S2, Bereczki D3, Embey-Isztin D4, Gulácsi L1, Balogh O1, V. Hevér N1,
Torzsa P3, Péntek M1
1Corvinus University of Budapest, Budapest, Hungary, 2University of Pécs, Pécs, Hungary,
3Semmelweis University, Budapest, Hungary, 4National Institute of Oncology, Budapest, Hungary
OBJECTIVES: Peripheral neuropathic pain (PNP) is a complex type of pain initiated
by a primary lesion or dysfunction in the nervous system and causes large impact
on health related quality of life (HRQL). While PNP in diabetes is in focus much less
attention is given to non-diabetic PNP. The main aims of present study were to
screen patients in GP practices for non-diabetic PNP, assess their HRQL and explore
key influential variables. METHODS: Non-diabetic patients aged 30 years were
recruited in 10 general practices in Hungary. At first, patients filled in the PainDe-
tect Questionnaire (PD-Q). Patients achieving 13 PD-Q score (unclear or possible
neuropathic pain) were further assessed by DN4 (Neuropathic Pain Diagnostic
Questionnaire). The cut-off value for the diagnosis of neuropathic pain in the DN4
is a total score of 4/10. Patients with PD-Q score 18 or DN4 score 4 were consid-
ered to be PNP patients. They completed the EQ-5D questionnaire and GPs provided
demographic data. RESULTS: One hundred and eleven patients with non-diabetic
PNP were selected. Among them there were more women (69%), mean age was 62
(SD14) years. Only 15 (14%) patients have already had prior PNP diagnosis at
inclusion. EQ-5D index showed 58% decrease compared to a perfect health state
and 44% decrease to the gender and age matched Hungarian population (0.42 vs.
0.75, p0.001). The pain/discomfort dimension was the most affected in the EQ-5D,
96% of patients reported some or serious problem. Similar ratios for mobility, self-
care, usual activities and anxiety dimensions were 83%, 37%, 82% and 83%. Average
(SD) EQ-5D score of patients with mild, moderate and severe average pain were 0.56
(0.29), 0.43 (0.29) and 0.29 (0.27). The differences were significant (p0.014).
CONCLUSIONS: Our research showed that non-diabetic neuropathic pain is poorly
A556 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
diagnosed and a strong relationship was demonstrated between neuropathic pain
and HRQL.
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OBJECTIVES: Huntington’s disease (HD) is a rare neurodegenerative disease lead-
ing to sustained disability for patients, and poor quality of life (QoL) for patients and
their caregivers. This study, conducted in Spain as a part of an international survey,
investigated the QoL of family carers of patients with HD. METHODS: The hospital
‘Hospital Ramon y Cajal’ provided their patients with two self-reported question-
naires (one for patient and one for his/her caregiver). Caregivers were asked to
answer sociodemographic questions and complete the short version of the HD
Quality of Life Battery for Carers (HDQoL-C), a previously validated questionnaire
by Aubeeluck A. and Buchanan H. The determinants of caregiver QoL relating to
patients’ clinical characteristics (motor, functional, behavioural disorders) were
studied by regression analysis, adjusting for age, sex and occupational categories.
The relationship between QoL of patients and caregivers was also explored using
Pearson’s correlations. RESULTS: Sixty caregivers and 59 patients were included.
The mean ( standard deviation; SD) age of caregivers was 49 (14) years and 73%
were female. 10% were completely unsatisfied with their overall QoL and 12% were
totally satisfied. Patients’ motor score and functional score were found to be drivers
of the Spanish caregivers’ QoL (p0.02, for both) but the behavioral score was not
(p0.18). The caregiver total QoL score was not significantly correlated with pa-
tients EQ-5D index score (p0.11) and HD-specific QOL assessment, H-QOL-I
(p0.36). CONCLUSIONS: Caregiver’s QoL worsens as patient motors’ symptoms
and functional capacity deteriorate. Patient and caregiver QoL was not directly
correlated. A limitation of this study is the low sample size; HD is a rare disease,
which made it difficult to recruit large sample.
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OBJECTIVES: The quality of life (QoL) of informal caregivers can be adversely af-
fected by a number of factors. This issue, however, has not been well explored for
carers of people with Parkinson’s disease (PD). This study aims to determine the
main influences on carer QoL in this population. METHODS: Carers completed the
PDQ-Carer, a 29 item instrument incorporating four dimensions (Social and Per-
sonal Activities, Anxiety and Depression, Self-Care and Stress). PWP completed the
PDQ-39, a 39 item instrument containing eight dimensions (Mobility, Activities of
Daily Living, Emotional Well-Being, Stigma, Social Support, Cognitions, Communi-
cation and Bodily Discomfort). Regression analyses were performed to identify
factors related to carer QoL. RESULTS: The sample comprised 238 carers (mean age
68.20 years) and 238 PWP (mean age 71.64). The mean duration of caring was 8.13
years. Carer Social and Personal Activities were significantly related to caregiver
age (p 0.01), PWP Mobility (p 0.01) and Cognitions (p 0.01). Carer Anxiety and
Depression were significantly related to caregiver age (p  0.01), length of caregiv-
ing (p  0.05), PWP Emotional Well-Being (p  0.05), Cognitions (p  0.01) and
Communication (p  0.05). Caregiver Self-Care was significantly related to care-
giver age (p  0.05), length of caregiving (p  0.05), PWP Mobility (p  0.01), Emo-
tional well-being (p  0.05) and Cognitions (p  0.05). Caregiver Stress was signifi-
cantly related to caregiver age (p  0.05), length of caregiving (p  0.01) and PWP
Cognitions (p 0.01). CONCLUSIONS: Results suggest multiple influences on care-
giver QoL. Carer age and length of time in the caregiving role appear to be of
particular importance, as do PWP levels of mobility and cognitive impairment.
Practitioners and service providers should be aware of the heightened impact of PD
on carers over time and also as PWP symptoms deteriorate.
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OBJECTIVES: To report the impact of BG-12 (dimethyl fumarate) on patient health-
related quality of life (HRQoL) in DEFINE, a 2-year, randomized, double-blind, pla-
cebo-controlled, multicentre study of the efficacy and safety of BG-12 in patients
with relapsing–remitting multiple sclerosis (RRMS). METHODS: Patients aged
18–55 years with RRMS (McDonald criteria) and an Expanded Disability Status Scale
(EDSS) score of 0–5.0 were randomized 1:1:1 to placebo or oral BG-12 240 mg twice
(BID) or three times daily (TID). A Short Form (SF)-36 questionnaire was adminis-
tered to assess health status and HRQoL on 8 multi-item 100-point scales at base-
line, 24 weeks, 1 year and 2 years; higher scores indicated better HRQoL. These
scores were used to calculate the Physical Component Summary (PCS) and Mental
Component Summary (MCS) scores. RESULTS: Overall, 1,234 patients were en-
rolled and treated. Mean baseline PCS and MCS scores decreased with increasing
disability (EDSS score). Mean SF-36 PCS scores increased from baseline to 2 years
with BG-12 BID (0.45) and TID (0.51) versus a decrease with placebo (1.36; both
p0.001), indicating an improvement in physical health and well-being. Similar
trends were observed on SF-36 MCS scores (BG-12 BID [0.20] and TID [1.05]
versus placebo [1.06]; p0.065 and p0.002, respectively). Most individual do-
main scores revealed a significant treatment effect for BG-12 BID at 6, 12, and 24
months. The proportion of patients who achieved clinically important improve-
ments in PCS and MCS scores (5-point change) was significantly higher in the
BG-12 groups versus placebo (all p0.05). CONCLUSIONS: Together with the signif-
icant effects on clinical endpoints (reduced proportion of patients relapsed, annu-
alized relapse rate, and disability progression) and magnetic resonance imaging
measures of disease activity, the demonstrated benefits on patient-reported
HRQoL further supports a potential role for BG-12 as a valuable oral treatment
option in patients with relapsing MS.
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OBJECTIVES: Hereditary angioedema (HAE) due to C1-INH deficiency is a rare or-
phan disease characterised by spontaneous attacks of oedema that interrupt the
normal attack-free state. HAE is known to impact patient quality of life (QoL) and
productivity but, despite a recent increase in treatment options, there remains a
shortage of data to quantify these important aspects of the HAE disease. Sweha-
Reg, a population based census of HAE in Sweden, implemented a retrospective
patient survey to address this data gap and define the burden of HAE in Sweden.
METHODS: A retrospective registry study of Swedish patients with HAE (captured
by the Sweha-Reg census). Data was collected using a paper-based survey. Patients
completed EQ5D-5L questionnaires for attack-free and acute HAE attack states. To
be included in the analysis, patients must have suffered an attack in the last 12
months. Questions related to patient demographics (age and sex) and other param-
eters (such as attack location and severity) were included to better understand the
burden of HAE. EQ5D-5L values were estimated for both HAE disease states and
then compared with other variables; utilities were also calculated. Patient-reported
sick-leave was analysed to understand the factors responsible for productivity loss
in patients with HAE. RESULTS: A total of 105 valid responses were analysed from
an initial mailing of 139 surveys (76% response rate). 94% of patients reported an
attack in the last 12 months. The total number of attacks reported per patient
during one year ranged from 1 to 120. A significant reduction in QoL scores between
the attack-free and acute attack states of HAE was observed. Also, attack location
and severity had a clear impact on the utility values. CONCLUSIONS: Results from
this Sweha-Reg study provide an insight to the significant impact on QoL and
productivity loss that HAE has on patients in Sweden.
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OBJECTIVES: To assess the follow-up level of the recommended guidelines for the
treatment of Multiple Sclerosis (MS) developed by the Spanish Neurology Society
(SEN) for the treatment of patients with relapsing remitting MS (RRMS).METHODS:
Non-interventional, retrospective, and multicenter study that recruited patients
with RRMS and clinical evolution of at least 5 years. Four hundred patients in 40
different centers are expected to be recruited in the ongoing study. The primary
variable of the study (follow-up and monitoring of the SEN Guidelines for the man-
agement of MS patients) has been obtained by researchers’ ad-hoc questionnaire
that includes activities and evaluation criteria taken into account when a thera-
peutic change should be considered. These changes should be made when there is
a presence of an inadequate clinical response defined by one or more of the follow-
ing circumstances: the same or higher number of relapses than during the previous
year, 2 relapses/year, one relapse and one gadolinium enhancing lesion per year,
and/or increase of 1 sustained point for the last six months without relapses (0.5 if
EDSS  5.5 or 1.5 if EDSS  0). RESULTS: The study is currently finalizing the
inclusion of patients and the analyses are just being initiated. The FUTURA Study
will evaluate the circumstances that determine treatment choice, therapeutic
changes, and monitoring and control issues based on patient clinical history de-
tails, and if the decision to change treatment is made following the SEN guidelines
for the treatment of such patients. CONCLUSIONS: The FUTURA Study will assess
the follow-up and compliance of the Spanish Neurology Therapeutic MS Guidelines
recommendations for the treatment of RRMS patients by Spanish neurologists.
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